Application of butylphthalide in preparation of medicament for treating bronchial asthma

Abstract

The invention provides novel medical application of butylphthalide, i.e. the application of the butylphthalide in the preparation of a medicament for treating the bronchial asthma. The experimental research on the spasmolysis of the butylphthalide on the isolated tracheal smooth muscle of a guinea pig and the influence of the butylphthalide on the incubation period of asthma of the guinea pig shows that the butylphthalide in the concentration range of 3.68*10-6 to 3.68*10-4g / mL has obvious spasmolysis on the tracheal smooth muscle of the guinea pig in the isolated spasticity caused by 5*10-6g / mL of acetylcholine or histamine. On the basis of continuously applying the butylphthalide to the guinea pig which is sensitive for the acetylcholine and the histamine for 10 days, a mixture of the acetylcholine and the histamine is atomized and sucked and the incubation period of asthma is observed. A result shows that 30 mg / kg and 90 mg / kg of butylphthalide has an effect of relieving the tracheospasm of the guinea pig, which is caused by the acetylcholine and the histamine. Therefore, the butylphthalide has a treatment effect on the asthma guinea pig and the treatment effect of the butylphthalide on the asthma guinea pig is related to the effect of inhibiting Ca2+ inner flow and expanded tracheal smooth muscle of the butylphthalide.

Description

technical field [0001] The invention belongs to the field of medicine, and relates to the medical use of a compound butylphthalide, in particular to the application of a compound butylphthalide as an active ingredient in the preparation, prevention or treatment of bronchial asthma. Background technique [0002] Bronchial asthma (referred to as asthma) is a chronic airway inflammatory disease involving a variety of inflammatory cells, especially mast cells, eosinophils and T lymphocytes. In susceptible persons, this inflammation can cause recurrent wheezing, Symptoms such as shortness of breath, chest tightness, and cough often occur at night or in the early morning, and the airway is more responsive to various stimuli. The 2006 version of the Global Initiative for Asthma (The Global Initiative for Asthma, GINA) proposed that the global incidence of asthma is 1%-18%, and there are about 300 million asthma patients in the world; the prevalence of asthma in my country is about ...

AI Technical Summary

Problems solved by technology

[0003] At present, the chemicals used to treat asthma mainly include glucocorticoids, beta 2 Receptor agonists and xanthines and other drugs, although the curative effect is reliable, but the adverse reactions are relatively large

Glucocorticoids are effective, but they have a wide range of effects, and long-term use can easily cause a variety of serious adverse reactions; β 2 Receptor agonists are commonly used drugs for acute attacks of asthma, and xanthine drugs are suitable for various types of asthma, but they can excite the heart while exerting therapeutic effects, and even cause arrhythmia

Images